Search

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

Interchangeable Biosimilar Now on Express Scripts® Formulary

Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

How Simulation is Changing the Game in Biotherapeutic Drug Development

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies

Schizophrenia: Trial Results Show Advance in Cognition | BI US

Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint.

Jardiance® (empagliflozin) Shows Reduction in CV Risk & Death | Boehringer Ingelheim US

BI & Eli Lilly & Co.’s JARDIANCE reduced risk of CV death, non-fatal heart attack or non-fatal stroke by 14%. View ISI, PI and Med Guide.

Jardiance® (empagliflozin) Tablets Studied in CKD | Boehringer Ingelheim US

BI & Eli Lilly & Co. announce plans for a new trial investigating JARDIANCE for the treatment of CKD. View ISI, PI and Med Guide.

Jardiance® (empagliflozin) analysis reinforces established safety profile

Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis

BI Awards Showcase Veterinary Talent | Boehringer Ingelheim US

Click here to read more on the Boehringer Ingelheim annual awards showcasing and celebrating emerging veterinary talent across the USA.

Financial year 2018

Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia

Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

Improving Access to Clinical Trials

Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials

Clinical Development and Operations

Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.

Baseball Legend Bernie Williams Calls on the Public to Join Queen Latifah, The Bacon Brothers, Paul Shaffer, as Judges of the Breathless® Ballad Challenge

New agreement with Quallent expands biosimilar access

Boehringer Ingelheim enters private label agreement for biosimilar

Data Shows Jardiance® (empagliflozin) Cardiorenal Risk Reductions | Boehringer Ingelheim US

The EMPA-REG OUTCOME® trial shows JARDIANCE reduces CV and renal risk in adults with T2D & known CV disease. View ISI, PI & Med Guide.

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’

First half 2019: High levels of investment in R&D and robust organic growth

Consumer Health Data Privacy Statement

This Consumer Health Data Privacy Statement applies to “Consumer Health Data,” as that term has been defined under applicable law.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers